dc.contributor.author |
Buyuktiryaki, Mehmet |
|
dc.contributor.author |
Alyamac Dizdar, Evrim |
|
dc.contributor.author |
Okur, Nilufer |
|
dc.contributor.author |
Sari, Fatmanur |
|
dc.contributor.author |
Bezirganoglu, Handan |
|
dc.contributor.author |
Canpolat, Fuat Emre |
|
dc.contributor.author |
Uras, Nurdan |
|
dc.contributor.author |
Oguz, Serife Suna |
|
dc.date.accessioned |
2022-03-08T09:34:59Z |
|
dc.date.available |
2022-03-08T09:34:59Z |
|
dc.date.issued |
2019 |
|
dc.identifier.citation |
Buyuktiryaki, M., Alyamac Dizdar, E., Okur, N., Bezirganoglu, H., Sari, F., Uras, N., Emre Canpolat, F., & Suna Oguz, S. (2021). Postnatal hydrocortisone therapy for the treatment of bronchopulmonary dysplasia in very low birth weight infants . Annals of Medical Research |
en_US |
dc.identifier.uri |
http://hdl.handle.net/11616/54729 |
|
dc.description.abstract |
Aim: Corticosteroids are widely used to prevent and treat bronchopulmonary dysplasia (BPD) due to their strong anti-inflammatory effects. We aim to evaluate the outcomes of late onset systemic hydrocortisone (HC) therapy in very low birth weight infants with BPD.Material and Methods: The medical records of 706 preterm infants with gestational age ≤ 30 weeks over a 4-year period were retrospectively reviewed. Infants who required invasive/noninvasive respiratory support or ≥ 30% oxygen due to BPD and were treated with HC after the third postnatal week were included. The infants were divided into 3 groups according to respiratory support at the beginning of the HC treatment: mechanical ventilation (MV), noninvasive ventilation (NIV), and free oxygen.Results: Seventy-six (11.9%) infants in our cohort received HC therapy. In the MV group, 83.3% of the infants were successfully extubated after a median of 4 days (interquartile range [IQR], 2-8 days). In the NIV group, 83.9% of the infants required no longer respiratory support after a median of 6 days (IQR, 3-16 days). In the free oxygen group, none of the infants needed supplemental oxygen after a median of 8 days (IQR, 6-12 days). Conclusion: Late HC therapy facilitates extubating without adverse short-term effects, reduces the need of invasive and noninvasive ventilation, and facilitates discharge without supplemental oxygen. |
en_US |
dc.language.iso |
eng |
en_US |
dc.rights |
info:eu-repo/semantics/openAccess |
en_US |
dc.title |
Postnatal hydrocortisone therapy for the treatment of bronchopulmonary dysplasia in very low birth weight infants |
en_US |
dc.type |
article |
en_US |
dc.relation.journal |
Annals of Medical Research |
en_US |
dc.contributor.department |
İnönü Üniversitesi |
en_US |